Higher doses of CD34+ peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLA-identical sibling transplantation

Leukemia

Volumn 17, Issue 5, 2003, Pages 869-875

  Mohty, M ^a   Bilger, K ^a   Jourdan, E ^b,p   Kuentz, M ^c   Michallet, M ^d   Bourhis, J H ^e   Milpied, N ^f   Sutton, L ^g   Jouet, J P ^h   Attal, M ⁱ   Bordigoni, P ^j   Cahn, J Y ^k   Sadoun, A ^l   Ifrah, N ^m   Guyotat, D ⁿ   Faucher, C ^a   Fegueux, N ^b   Reiffers, J ^o   Maraninchi, D ^a   Blaise, D ^a  

^a INSTITUT PAOLI CALMETTES   (France)

^b MONTPELLIER UNIVERSITY HOSPITAL   (France)

^c HENRI MONDOR HOSPITAL   (France)

^d EDOUARD HERRIOT HOSPITAL   (France)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f HÔTEL DIEU   (France)

^g Section of Radiology   (France)

^h LILLE UNIVERSITY HOSPITAL   (France)

ⁱ TOULOUSE UNIVERSITY HOSPITAL   (France)

^j UNIVERSITY HOSPITAL OF NANCY   (France)

^k UNIVERSITY HOSPITAL OF BESANÇON   (France)

^l POITIERS UNIVERSITY HOSPITAL   (France)

^m ANGERS UNIVERSITY HOSPITAL   (France)

ⁿ UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^o BORDEAUX UNIVERSITY HOSPITAL   (France)

^p NÎMES UNIVERSITY HOSPITAL   (France)

more..

Author keywords

Allogeneic myeloablative transplantation; CD34+ stem cells; Chronic GVHD; Leukemia

Indexed keywords

BUSULFAN; CD3 ANTIGEN; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; ETOPOSIDE; MELPHALAN; METHOTREXATE; STEROID;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CHRONIC DISEASE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG FORMULATION; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA TYPING; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; NEUTROPHIL; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; PROBABILITY; SIBLING; THROMBOCYTE; WHOLE BODY RADIATION;

EID: 0038189636     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402909     Document Type: Article

References (55)

1. Korbling M, Przepiorka D, Hub YO, Engel H, van Besien K, Giralt S et al. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood 1995; 85: 1659-1665.
2. Bensinger WI, Weaver CH, Appelbaum FR, Rowley S, Demirer T, Sanders J et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood 1995; 85: 1655-1658.
3. Schmitz N, Dreger P, Suttorp M, Rohwedder EB, Haferlach T, Loffler H et al. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood 1995; 85: 1666-1672.
4. Bensinger WI, Clift R, Martin P, Appelbaum FR, Demirer T, Gooley T et al. Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: a retrospective comparison with marrow transplantation. Blood 1996; 88: 2794-2800.
5. Russell JA, Brown C, Bowen T, Luider J, Ruether JD, Stewart D et al. Allogeneic blood cell transplants for haematological malignancy: preliminary comparison of outcomes with bone marrow transplantation. Bone Marrow Transplant 1996; 17: 703-708.
6. Przepiorka D, Anderlini P, Ippoliti C, Kbouri I, Fietz T, Thall P et al. Allogeneic blood stem cell transplantation in advanced hematologic cancers. Bone Marrow Transplant 1997; 19: 455-460.
7. Miflin G, Russell NH, Hutchinson RM, Morgan G, Potter M, Pagliuca A et al. Allogeneic peripheral blood stem cell transplantation for haematological malignancies - an analysis of kinetics of engraftment and GVHD risk. Bone Marrow Transplant 1997; 19: 9-13.
8. Schmitz N, Bacigalupo A, Hasenclever D, Nagler A, Gluckman E, Clark P et al. Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1998; 21: 995-1003.
9. Vigorito AC, Azevedo WM, Marques JF, Azevedo AM, Eid KA, Aranha FJ et al. A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies. Bone Marrow Transplant 1998; 22: 1145-1151.
10. Powles R, Mehta J, Kulkarni S, Treleaven J, Millar B, Marsden J et al. Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial. Lancet 2000; 355: 1231-1237.
11. Blaise D, Kuentz M, Fortanier C, Bourhis JH, Milpied N, Sutton L et al. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early stage leukemia: a report from the Societe Francaise de Greffe de Moelle. J Clin Oncol 2000; 18: 537-546.
12. Bensinger WI, Martin PJ, Storer B, Clift R, Forman SJ, Negrin R et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001; 344: 175-181.
13. Heldal D, Tjonnfjord G, Brinch L, Albrechtsen D, Egeland T, Steen R et al. A randomised study of allogeneic transplantation with stem cells from blood or bone marrow. Bone Marrow Transplant 2000; 25: 1129-1136.
14. Korbling M, Anderlini P. Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter? Blood 2001; 98: 2900-2908.
15. Mohty M, Kuentz M, Michallet M, Bourhis JH, Milpied N, Sutton L et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation: long term results of a randomized study. Blood 2002; 100: 3128-3134.
16. Bacigalupo A, Francesco F, Brinch L, Van Lint MT. Bone marrow or peripheral blood as a source of stem cells for allogeneic transplants. Curr Opin Hematol 2000; 7: 343-347.
17. Ryncarz RE, Anasetti C. Expression of CD86 on human marrow CD34(+) cells identifies immunocompetent committed precursors of macrophages and dendritic cells. Blood 1998; 91: 3892-3900.
18. Rondelli D, Anasetti C, Fortuna A, Ratta M, Arpinati M, Bandini G et al. T cell alloreactivity induced by normal G-CSF-mobilized CD34+ blood cells. Bone Marrow Transplant 1998; 21: 1183-1191.
19. Rondelli D, Lemoli RM, Ratta M, Fogli M, Re F, Curti A et al. Rapid induction of CD40 on a subset of granulocyte colony-stimulating factor-mobilized CD34(+) blood cells identifies myeloid committed progenitors and permits selection of nonimmunogenic CD40(-) progenitor cells. Blood 1999; 94: 2293-2300.
20. van Rhee F, Jiang YZ, Vigue F, Kirby M, Mavroudis D, Hensel NF et al. Human G-CSF-mobilized CD34-positive peripheral blood progenitor cells can stimulate allogeneic T-cell responses: implications for graft rejection in mismatched transplantation. Br J Haematol 1999; 105: 1014-1024.
21. Urbano-Ispizua A, Carreras E, Marin P, Rovira M, Martinez C, Fernandez-Aviles F et al. Allogeneic transplantation of CD34(+) selected cells from peripheral blood from human leukocyte antigen-identical siblings: detrimental effect of a high number of donor CD34(+) cells? Blood 2001; 98: 2352-2357.
22. Thomas E, Storb R, Clift RA, Fefer A, Johnson FL, Neiman PE et al. Bone-marrow transplantation (first of two parts). N Engl J Med 1975; 292: 832-843.
23. Santos GW, Tutschka PJ, Brookmeyer R, Saral R, Beschorner WE, Bias WB et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 1983; 309: 1347-1353.
24. Blume KG, Forman SJ, O'Donnell MR, Doroshow JH, Krance RA, Nademanee AP et al. Total body irradiation and high-dose etoposide: a new preparatory regimen for bone marrow transplantation in patients with advanced hematologic malignancies. Blood 1987; 69: 1015-1020.
25. Cahn JY, Bordigoni P, Souillet G, Pico JL, Plouvier E, Reiffers J et al. The TAM regimen prior to allogeneic and autologous bone marrow transplantation for high-risk acute lymphoblastic leukemias: a cooperative study of 62 patients. Bone Marrow Transplant 1991; 7: 1-4.
26. Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314: 729-735.
27. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man. A longterm clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217.
28. Farmer ER. The histopathology of graft-versus-host disease. Adv Dermatol 1986; 1: 173-188.
29. Sullivan KM, Agura E, Anasetti C, Appelbaum F, Badger C, Bearman S et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991; 28: 250-259.
30. Miettinen O. Estimability and estimation in case-referent studies. Am J Epidemiol 1976; 103: 226-235.
31. Cooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695-706.
32. Przepiorka D, Anderlini P, Saliba R, Cleary K, Mehra R, Khouri I et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 2001; 98: 1695-1700.
33. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 195; 53: 457-481.
34. Rothman KJ. Estimation of confidence limits for the cumulative probability of survival in life table analysis. J Chronic Dis 1978; 31: 557-560.
35. Mantel N, Haenzel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-748.
36. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol 1983; 1: 710-719.
37. Cox DR. Regression models and life-tables (with discussions), Series B. J R Statist Soc 1972; 34: 187-220.
38. Faucher C, le Corroller AG, Blaise D, Novakovitch G, Manonni P, Moatti JP et al. Comparison of G-CSF-primed peripheral blood progenitor cells and bone marrow auto transplantation: clinical assessment and cost-effectiveness. Bone Marrow Transplant 1994; 14: 895-901.
39. Faucher C, Le Corroller AG, Chabannon C, Viens P, Stoppa AM, Bouabdallah R et al. Autologous transplantation of blood stem cells mobilized with filgrastim alone in 93 patients with malignancies: the number of CD34+ cells reinfused is the only factor predicting both granulocyte and platelet recovery. J Hematother 1996; 5: 663-670.
40. Russel N, Gratwohl A, Schmitz N. The place of blood stem cells in allogeneic transplantation. Br J Haematol 1996; 93: 747-753.
41. Zaucha JM, Gooley T, Bensinger WI, Heimfeld S, Chauncey TR, Zaucha R et al. CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation. Blood 2001; 98: 3221-3227.
42. Gianni AM, Bregni M, Siena S, Villa S, Sciorelli GA, Ravagnani F et al. Rapid and complete hemopoietic reconstitution following combined transplantation of autologous blood and bone marrow cells. A changing role for high dose chemo-radiotherapy? Hematol Oncol 1989; 7: 139-148.
43. Martin PJ. The role of donor lymphoid cells in allogeneic marrow engraftment. Bone Marrow Transplant 1990; 6: 283-289.
44. Schmitz N, Beksaç M, Hasenclever D, Bacigalupo A, Ruutu T, Nagler A et al. Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard risk leukemia. Blood 2002; 100: 761-767.
45. Leung W, Ramirez M, Mukherjee G, Perlman EJ, Civin CI. Comparisons of alloreactive potential of clinical hematopoietic grafts. Transplantation 1999; 68: 628-635.
46. Reyes E, Garcia-Castro I, Esquivel F, Hornedo J, Cortes-Funes H, Solovera J et al. Granulocyte colony-stimulating factor (G-CSF) transiently suppresses mitogen-stimulated T-cell proliferative response. Br J Cancer 1999; 80: 229-235.
47. Volpi I, Perruccio K, Tosti A, Capanni M, Ruggeri L, Posati S et al. Postgrafting administration of granulocyte colony-stimulating factor impairs functional immune recovery in recipients of human leukocyte antigen haplotype-mismatched hemnatopoietic transplants. Blood 2001; 97: 2514-2521.
48. Arpinati M, Green CL, Heimfeld S, Heuser JE, Anasetti C. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood 2000; 95: 2484-2490.
49. Pan L, Delmonte Jr J, Jalonen CK, Ferrara JL. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood 1995; 86: 4422-4429.
50. Przepiorka D, Smith TL, Folloder J, Khouri I, Ueno NT, Mehra R et al. Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 1999; 94: 1465-1470.
51. Nash RA, Pepe MS, Storb R, Longton G, Pettinger M, Anasetti C et al. Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclos-porine and methotrexate. Blood 1992; 80: 1838-1845.
52. Deeg HJ. Prophylaxis and treatment of acute graft-versus-host disease: current state, implications of new immunopharmacologic compounds and future strategies to prevent and treat acute GVHD in high-risk patients. Bone Marrow Transplant 1994; 14: S56-S60.
53. Lee SJ, Klein JP, Barrett AJ, Ringden O, Antin JH, Cahn JY et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood 2002; 100: 406-414.
54. Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981; 304: 1529-1533.
55. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562.